Viyash Scientific Limited operates in pharmaceutical and scientific products, with opportunities linked to healthcare demand and specialized pharmaceutical applications. Growth in pharmaceutical consumption and outsourcing provides potential for expansion. New products, capacity additions, and international market penetration can support growth. Regulatory compliance, R&D requirements, raw-material costs, competition, and pricing pressure remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹9,659 cr | ₹3,149 cr | ₹214 cr | 52.8 | 4.19 | 3.32 | 9.8% | 3.2% | 17.5% | 0.15 | ₹225 cr | 15.4 | — |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 946 | 79 | 1.51 | +164.9% | +114.4% | 8.4% |
| Mar 2026 | 920 | 66 | 1.20 | +224.3% | +129.0% | 7.2% |
| Dec 2025 | 858 | 48 | 0.89 | +535.7% | +119.6% | 5.7% |
| Sep 2025 | 424 | 20 | 0.59 | +490.0% | +15.0% | 4.6% |
| Jun 2025 | 441 | 18 | 0.57 | +119.2% | +13.1% | 4.0% |
| Mar 2025 | 402 | 10 | 0.37 | turnaround | +11.2% | 2.6% |
| Dec 2024 | 391 | 6 | 0.14 | -57.6% | +18.7% | 1.7% |
| Sep 2024 | 369 | 6 | 0.10 | turnaround | +6.6% | 1.7% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✓ Pass |
| EPS growth accelerating over 3 quarters | ✗ Fail |
| Sales up 25%+, or sales growth accelerating | ✓ Pass |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Turtle | ✗ Close above the prior 55-session high · 281.20 ✗ Close above the prior 20-session high · 262.65 ✗ Close below the prior 20-session low · 220.62 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 1 - basing | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 6.5% — Return on capital (ROCE) · 17.5% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 62/100 | Average |
| Graham | ✗ Price at or below the Graham number · Graham number 79.24 ✗ P/E 15 or less · P/E 52.8 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 3.32 ✓ Current ratio 2 or more · 2.38 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 36/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✓ ROA rising ✓ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✓ Current ratio rising · 2.38 ✗ No new shares issued ✓ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 7/9 | Strong |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIYASH this stock | -11.4 | -16.4 | +6.7 | — | — | — | 52.8 | 3.32 | 9.8 | 17.6 | — | 0.15 | 15.4 | 9,659 | 3,149 | 214 | 4.2 | — |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ZIMLAB | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |